We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sorrento Therapeutics (SRNE) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Sorrento Therapeutics (SRNE - Free Report) closed at $7.92 in the latest trading session, marking a -1.98% move from the prior day. This move lagged the S&P 500's daily loss of 1.86%. At the same time, the Dow lost 2.3%, and the tech-heavy Nasdaq lost 1.64%.
Prior to today's trading, shares of the biopharmaceutical company had lost 12.08% over the past month. This has lagged the Medical sector's gain of 2.07% and the S&P 500's gain of 7.63% in that time.
Investors will be hoping for strength from SRNE as it approaches its next earnings release. The company is expected to report EPS of -$0.21, up 50% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.32 million, up 78.46% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.96 per share and revenue of $2.05 billion. These totals would mark changes of +333.96% and +6411.95%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for SRNE. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. SRNE is holding a Zacks Rank of #4 (Sell) right now.
Investors should also note SRNE's current valuation metrics, including its Forward P/E ratio of 1.63. Its industry sports an average Forward P/E of 23.71, so we one might conclude that SRNE is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 182, which puts it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sorrento Therapeutics (SRNE) Dips More Than Broader Markets: What You Should Know
Sorrento Therapeutics (SRNE - Free Report) closed at $7.92 in the latest trading session, marking a -1.98% move from the prior day. This move lagged the S&P 500's daily loss of 1.86%. At the same time, the Dow lost 2.3%, and the tech-heavy Nasdaq lost 1.64%.
Prior to today's trading, shares of the biopharmaceutical company had lost 12.08% over the past month. This has lagged the Medical sector's gain of 2.07% and the S&P 500's gain of 7.63% in that time.
Investors will be hoping for strength from SRNE as it approaches its next earnings release. The company is expected to report EPS of -$0.21, up 50% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.32 million, up 78.46% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.96 per share and revenue of $2.05 billion. These totals would mark changes of +333.96% and +6411.95%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for SRNE. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. SRNE is holding a Zacks Rank of #4 (Sell) right now.
Investors should also note SRNE's current valuation metrics, including its Forward P/E ratio of 1.63. Its industry sports an average Forward P/E of 23.71, so we one might conclude that SRNE is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 182, which puts it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.